Identifying therapeutic vulnerabilities of bone marrow-driven recurrence of ER+ breast cancer
Ended Project Grant Awarded Last action
- Award ID
- W81XWH2210119
- Recipient
-
The University Of Akron UEI DFNLDECWM8J8
- Awarding agency
-
Medical Command
Department of the Army, Department of Defense
- Obligated
- $1,132,200
Award facts
- Assistance listing
- 12.420 Military Medical Research and Development
- Completion date
- Place of performance
- Akron, OH 44325, USA
Award details come from USAspending.gov.
About this award
The University of Akron received a $1,132,200 Project Grant award from the Department of the Army Medical Command on September 30, 2022 to identify therapeutic vulnerabilities of bone marrow-driven recurrence of ER+ breast cancer. The grant is being used to fund research under the Military Medical Research and Development program (CFDA 12.420) through September 29, 2025.
The Military Medical Research and Development program supports basic, applied, and advanced biomedical research with the goals of transforming military and public health care through innovative research and investigating medical solutions for battlefield wounds. This award will allow researchers at The University of Akron to investigate therapeutic approaches for bone marrow-driven recurrence of estrogen receptor-positive breast cancer, advancing the program's mission to develop medical solutions through impactful research.
Quick answers
Who received award W81XWH2210119?
W81XWH2210119 was awarded to The University Of Akron by Medical Command (Department of the Army) on September 30, 2022.
How much is award W81XWH2210119 worth?
$1,132,200 has been obligated on W81XWH2210119.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award